|
|
The presentation will highlight the underlying technology and pilot study findings of an ambulatory RSA biofeedback device named the StressEraser. The StressEraser is a class II, (510(k) exempt) FDA regulated medical device marketed for the purposes of stress reduction, relaxation, and relaxation training. Two pilot studies, one in an outpatient clinic and one using beta testers reporting high stress levels, were conducted to test the usability and effectiveness of the device according to marketing claims. Results indicate that the device can be easily integrated into practice, yields high compliance rates, and is an effective adjunctive and stand-alone stress reduction device.
Details:
Plenary #241): The StressEraser: Overview and Pilot Study Findings
Contact Info: Fred Muench Ph.D. | |||||||
|